Sold as Moban. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 16, 2026, FDA lists 3 applications for Molindone Hydrochloride (sold as Moban), first approved Jan 18, 1974, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Molindone HCl | Part D | $113K | -69% | 50 |
| Jan 18, 1974 | MobanNDA 17111 · New molecular entity | Chartwell Rx | 36 | Discontinued |
| Dec 28, 1979 | MobanNDA 17938 · New dosage form | Endo Pharms | 12 | Discontinued |
| Mar 20, 2015 | Molindone HydrochlorideANDA 90453 | Epic Pharma LLC | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA